Loading…
← CockpitCompetitor Analysis › 002584.SZ Xilong Scientific Co., Ltd. Class AOpen in the cockpit ↗

Xilong Scientific Co., Ltd. Class A002584.SZCompetitor analysis, valuation and peers

China · CNY·Materials›Chemicals: Specialty
Momentum neutral 56
Mkt cap
$632M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$36.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-4.3 pp
WACC 6.9%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥7.20
1D-2.3%
1W+2.7%
1M-19.6%
3M-2.0%
6M-10.6%
YTD-21.8%
1Y-15.8%
ATR %4.9%
52w lowhigh38.7% off high

What Xilong Scientific does

Employees: 1,420

Xilong Scientific at a glance

Size Xilong Scientific (002584.SZ) is a China Materials company (Chemicals: Specialty) with a market value of $632M, the 3296th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥7.20 on 6 Nov 2026.

Performance Over six months the shares fell 10.6%, against -22.0% for the median peer and -16.4% for the China market (cap-weighted) — 8th highest of 20 in its peer set.

Growth Revenue grew 22.8% over the last twelve months (peer median +9.8%); the operating margin is 1.4% (peer median 5.5%).

Valuation It trades at 0.7× enterprise value to sales against a peer median of 2.1× (4th cheapest of 20).

Capital Return on invested capital runs 4.3 points below its cost of capital (6.9% WACC).

Relative performance

8010012014011 May 202611 Aug 20266 Nov 2026002584.SZ 89Peer median 74
Six months, rebased to 100: Xilong Scientific against the median of its 20 peers (local-currency closes).

Xilong Scientific financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥8.27BCN¥7.32BCN¥7.81BCN¥7.09BCN¥6.18B
Revenue growth—-6%+10%+15%—
Gross profitCN¥538MCN¥474MCN¥484MCN¥435MCN¥411M
EBITDACN¥201MCN¥212MCN¥209MCN¥166MCN¥132M
Net incomeCN¥39.2M-CN¥75.5MCN¥61.8MCN¥33.3MCN¥89.1M
Free cash flow-CN¥480M-CN¥38.6MCN¥249M-CN¥509M-CN¥515M
Capital expenditureCN¥177MCN¥100MCN¥44.9MCN¥215MCN¥324M
Total debtCN¥1.73BCN¥1.74BCN¥1.61BCN¥1.65BCN¥2.00B

Quarterly statements and history in the cockpit →

Xilong Scientific competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-40%-20%0%300848300478004000801447700008193012460021656037900933703007580024551709002637BALAMINES603276002584.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Xilong Scientific is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%0×5×10×3008483004780040008014477000081930124668819600216560379009337030075825531709002637BALAMINES4028002584.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Xilong Scientific is the large dot.

Xilong Scientific competitors and peer comparison

How Xilong Scientific compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Xilong Scientific against its 20 peers (data as of 6 Nov 2026)
Measure002584.SZPeer medianRank in peer set
1-month return-19.6%-10.1%4th lowest of 21
6-month return-10.6%-22.0%8th highest of 20
Distance from 52-week high-38.7%-47.5%9th highest of 21
Revenue growth (TTM)+22.8%+9.8%6th highest of 21
Operating margin1.4%5.5%8th lowest of 21
EV / Sales0.7×2.1×4th cheapest of 20
ROIC minus cost of capital-4.3 pp-2.0 pp8th lowest of 20
Net debt / EBITDA5.9×-0.1×most indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Xilong Scientific 002584.SZChina$632M-11%+23%1%0.7×n/an/a
Miracll Chemicals 300848.SZChina$632M-45%+23%1%2.8×n/an/a
Hangzhou Gaoxin Materials Technology 300478.SZChina$631M+11%-21%-9%12.6×30.8%-0.9%
LOTTE Fine Chem 004000.KSSouth Korea$634M-51%+18%7%0.4×-8.2%+6.8%
Chori 8014.TJapan$629M-6%+3%4%0.2×-13.4%+6.7%
Allied Supreme 4770.TWTaiwan$629M+12%-15%19%3.6×3.4%+12.4%
Yueyang Xingchang Petro-Chemical 000819.SZChina$636M-29%+44%1%1.0×n/an/a
Hubei Hongyuan Pharmaceutical Technology 301246.SZChina$639M-47%+45%12%1.5×n/an/a
Longyan Zhuoyue New Energy 688196.SSChina$622M-38%+2%1%1.4×n/an/a
Hongbaoli 002165.SZChina$645M-32%+10%-19%2.0×n/an/a
Argus (Shanghai) Textile Chemicals 603790.SSChina$618M-11%+21%14%4.2×11.7%+0.7%
Foosung 093370.KSSouth Korea$648M-38%+27%8%2.1×n/an/a
Anshan Hifichem 300758.SZChina$615M-22%+11%9%3.0×15.5%+8.2%
Beijing Shougang LanzaTech Technology 2553.HKHong Kong$653Mn/a0%-45%9.8×n/an/a
Jiangsu Baichuan High-Tech New Materials 002455.SZChina$656M-42%+9%1%1.6×n/an/a
Formosan Union Chemical 1709.TWTaiwan$607M+128%-3%14%2.2×-1.6%+1.2%
Waga Energy WAGA.PAFrance$659M-3%+7%-20%n/an/an/a
Zanyu Technology 002637.SZChina$605M-34%-3%3%0.5×-0.9%+11.0%
Balaji Amines BALAMINES.NSIndia$604M+15%+21%19%3.5×n/an/a
Ishihara Sangyo Kaisha 4028.TJapan$596M-22%+1%11%0.9×1.1%+8.8%
Jiangsu Hengxing New Material Technology 603276.SSChina$596M+7%+29%8%3.3×18.5%+15.2%

Questions

Which companies are Xilong Scientific's closest peers?
The cockpit's peer set: Miracll Chemicals (300848.SZ), Hangzhou Gaoxin Materials Technology (300478.SZ), LOTTE Fine Chem (004000.KS), Chori (8014.T), Allied Supreme (4770.TW), Yueyang Xingchang Petro-Chemical (000819.SZ), Hubei Hongyuan Pharmaceutical Technology (301246.SZ), Longyan Zhuoyue New Energy (688196.SS).
Is Xilong Scientific expensive compared with its peers?
On ev / sales it trades at 0.7× against a peer median of 2.1×, 4th cheapest of 20 in its peer set.
How has Xilong Scientific stock performed?
Over six months to 6 Nov 2026 the shares returned -10.6% against -22.0% for the median peer; over one year -15.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.